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BACKGROUND AND PURPOSE
Proteinase activated receptor 2 (PAR2) is a GPCR associated with inflammation, metabolism and disease. Clues to
understanding how to block PAR2 signalling associated with disease without inhibiting PAR2 activation in normal physiology
could be provided by studies of biased signalling.
EXPERIMENTAL APPROACH
PAR2 ligand GB88 was profiled for PAR2 agonist and an tagonist properties by several functional assays associated with
intracellular G-protein-coupled signalling in vitro in three cell types and with PAR2-induced rat paw oedema in vivo.
KEY RESULTS
In HT29 cells, GB88 was a PAR2 antagonist in terms of Ca2+ mobilization and PKC phosphorylation, but a PAR2 agonist in
attenuating forskolin-induced cAMP accumulation, increasing ERK1/2 phosphorylation, RhoA activation, myosin phosphatase
phosphorylation and actin filament rearrangement. In CHO-hPAR2 cells, GB88 inhibited Ca2+ release, but activated Gi/o and
increased ERK1/2 phosphorylation. In human kidney tubule cells, GB88 inhibited cytokine secretion (IL6, IL8, GMCSF, TNF-α)
mediated by PAR2. A rat paw oedema induced by PAR2 agonists was also inhibited by orally administered GB88 and
compared with effects of locally administered inhibitors of G-protein-coupled pathways.
CONCLUSIONS AND IMPLICATIONS
GB88 is a biased antagonist of PAR2 that selectively inhibits PAR2/Gq/11/Ca2+/PKC signalling, leading to anti-inflammatory
activity in vivo, while being an agonist in activating three other PAR2-activated pathways (cAMP, ERK, Rho) in human cells.
These findings highlight opportunities to design drugs to block specific PAR2-linked signalling pathways in disease, without
blocking beneficial PAR2 signalling in normal physiology, and to dissect PAR2-associated mechanisms of disease in vivo.
Abbreviations
dtpa, diethylene triamine pentaacetic acid; FITC, fluorescein isothiocyanate; GB88, 5-isoxazoyl-Cha-Ile-spiroindene-1,4-
piperidine; HT-29, human colon adenocarcinoma grade II cell line; HTEC, human tubule epithelial cells; i.pl.,
intra-plantar; MEK, mitogen-activated kinase; MYPT, myosin phosphatase; PAR2, proteinase activated receptor 2; PTX,
Pertussis toxin; RhoA, Ras homologue gene family, member A; ROCK, Rho-associated protein kinase
Introduction
Proteolytic enzymes (proteases) play important, though
incompletely defined, roles in regulating cell signalling and
mammalian physiology (Heutinck et al., 2010; Adams et al.,
2011; Di Cera, 2011; Vergnolle and Chignard, 2011;
Hollenberg et al., 2014). Inhibitors of specific proteases have
successfully progressed through the clinic (Leung et al., 2000;
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Abbenante and Fairlie, 2005; Turk, 2006). However, many
proteases are involved in most diseases and each protease
usually has pleiotropic functions in both normal physiology
and disease (Cudic and Fields, 2009; Pejler et al., 2010;
Sharony et al., 2010; Moore and Crocker, 2012). A common
cellular target of several proteases, as well as more selective
modulation of the functions induced by proteases, may be
necessary for more specific and more effective drugs. One
such target is the proteinase activated receptor 2 (PAR2;
nomenclature follows Alexander et al., 2013a), which is a
membrane-spanning GPCR that is the target of a range of
serine proteases (Adams et al., 2011; Ramachandran et al.,
2012).
PAR2 has a unique activation mechanism. Its N-terminal
domain is pruned by extracellular serine proteases, such as
trypsin, tryptase, tissue factor TF-FVII-FXa, kallikreins and
human leukocyte elastase (Barry et al., 2006; Ramachandran
et al., 2012). If productively cleaved, the new N-terminus of
PAR2 self-activates by inducing intracellular G-protein-
coupled or β-arrestin-mediated signalling pathways, leading
to a diverse range of intracellular and physiological
responses. While activated PAR2 couples to Gq/11, Gs, Gi/o and
G12/13 (Adams et al., 2011; Hirota et al., 2012), individual
coupled pathways seem to be protease-, cell- and context-
dependent, and there is conflicting evidence derived from
different conditions. Furthermore, PAR2 can signal indepen-
dently of G-proteins via ß-arrestin1/2 (Nichols et al., 2012).
PAR2 is an important mediator in many animal models of
inflammatory diseases, including asthma (Cocks et al., 1999),
pancreatitis (Kawabata et al., 2006), irritable bowel syndrome
(Cenac et al., 2007), colitis (Lohman et al., 2012b), arthritis
(Lohman et al., 2012a), glomerulonephritis (Moussa et al.,
2007), obesity and diabetes (Badeanlou et al., 2011; Lim et al.,
2013).
Recently, we reported the discovery of a new, selective and
orally active antagonist of PAR2, 5-isoxazoyl-Cha-Ile-
spiroindene-1,4-piperidine (GB88; Barry et al., 2010; Suen
et al., 2012). It binds at high nM to low μM concentrations to
PAR2 on the cell surface and antagonizes intracellular
calcium release induced in many human, rat and mouse cell
types by either synthetic peptide (SLIGRL-NH2, SLIGKV-NH2,
2f-LIGRLO-NH2), peptidomimetic (GB110) or endogenous
protease (trypsin, tryptase) agonists of PAR2. GB88 also inhib-
ited inflammation in rat models of PAR2-induced paw
oedema (Barry et al., 2010; Suen et al., 2012), PAR2 agonist- or
TNBS-induced colitis (Lohman et al., 2012b), collagen-
induced arthritis (Lohman et al., 2012a) and diet-induced
obesity, adipose and macrophage inflammation, insulin sen-
sitivity and cardiovascular remodeling (Lim et al., 2013).
The present study reports the surprising finding that the
anti-inflammatory PAR2 antagonist GB88 activates a range of
other PAR2-mediated signalling pathways. The study reports
the regulation of PAR2-mediated intracellular signalling path-
ways by GB88, providing important newmechanistic insights
to PAR2-dependent signalling and inflammatory activity in
vivo and their potential for modulation by PAR2 ligands. Our
goal was to understand the spectrum of effects of this new
PAR2 ligand, which has important anti-inflammatory prop-
erties in vivo after oral administration, and to use GB88 to
mechanistically dissect PAR2 signalling. The differential and
unique spectrum of effects of GB88 on PAR2-mediated intra-
cellular signalling pathways reveals potentially useful ligand-
induced biased signalling that, in this particular paper,
highlights the relevance of the Gq/11-Ca2+ signalling pathway
in PAR2-mediated inflammation in human cells and in PAR2-
induced rat paw oedema. The research uncovered a pathway-
selective antagonist with potentially valuable uses as a new
tool for selectively inhibiting Gq signalling in vitro and in vivo.
Methods
Cell culture
All cell culture reagents were purchased from Invitrogen
(Carlsbad, CA, USA) and Sigma-Aldrich (St. Louis, MO, USA).
Human colorectal carcinoma human colon adenocarcinoma
grade II cell line (HT-29) and CHO cells were cultured in
medium at 37°C and 5% CO2 according to American Tissue
Culture Collection instructions. HT-29 cells were grown in
DMEM and CHO cells were grown in F12 supplemented with
200 μg·mL−1 hygromycin B. All media were supplemented
with 10% FBS, 100 units·per mL penicillin and 100 units·per
mL streptomycin. During cell culture passage, cell dissocia-
tion solution (Sigma-Aldrich) was used to dissociate cells
from the surface of culture flasks and cells were counted
manually using a haemocytometer or automated cell counter.
Competitive binding assay
Assays were performed as described (Hoffman et al., 2012).
Cells were seeded overnight in a 384-well plate at a density of
2500 cells per well. On the day of experiment, media was
aspirated and cells were washed with PBS followed by 2%
BSA blocking for 1 h at 37°C. After blocking, cells were
simultaneously exposed to 2f-LIGRLO(diethylene triamine
pentaacetic acid; dtpa)-NH2 (300 nM) and different con-
centrations of 2f-LIGRLO-NH2 for 15 min. GB88 was
pre-incubated for 15 min prior to the addition of
2f-LIGRLO(dtpa)-NH2 (300 nM) due to its slow on-rate (Suen
et al., 2012). Cells were then washed three times with PBS
supplemented with 20 μM EDTA, 0.01% Tween and 0.2%
BSA. After washings, cells were then incubated with 40 μL of
DELFIA enhancement solution (Perkin Elmer, Santa Clara,
CA, USA) for 90 min. Fluorescence was determined with ter-
minal restriction fragment analysis (Pherastar FS, BMG
Labtech): 340 nm excitation followed by 400 μs delay before
a 400 μs 615 nm emission.
Isolation and primary culture of human
tubule epithelial cells (HTEC)
Use of human renal tissue for primary culture was reviewed
and approved by the Princess Alexandra Hospital Research
Ethics Committee. Informed consent was obtained prior to
each operative procedure. Segments of macroscopically and
histologically normal renal cortex (5–10 g) were obtained
aseptically from the non-cancerous pole of adult human
kidneys removed surgically because of small renal cancers.
Patients were otherwise healthy.
The method for isolation and primary culture of HTEC is
fully described elsewhere (Vesey et al., 2005; 2007; 2009; Qi
et al., 2007). Briefly, the cortical tissue was minced finely,
washed several times and agitated for 20 min at 37°C in a
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Krebs-Henseleit buffer (KHB) containing collagenase type II
(1 mg·mL−1). Cold KHB was added and the solution passed
through a 297 μm sieve (50 Mesh, Sigma). After washing
three times, the tubular fragments were re-suspended in 45%
Percoll – KHB and centrifuged at 20 000× g. A high-density
band, previously shown to be tubule fragments, was removed
and cultured in a serum free, hormonally defined DMEM/F12
media (containing 10 ng·mL−1 epidermal growth factor,
5 μg·mL−1 insulin, 5 μg·mL−1 transferrin, 50 nM hydrocorti-
sone, 50 μM PGE1, 50 nM selenium and 5 pM triiodothyro-
nine). All experiments were performed on confluent passage
2 HTEC made quiescent by two washes followed by incuba-
tion for 24 h in serum and growth factor free DMEM/F12
media.
Intracellular calcium mobilization
Cells were grown to 80% confluence. Prior to experiment,
cells were seeded overnight in 96-well black wall, clear
bottom, plates at approximately 5 × 104 cells per well. On the
day of experiment, supernatant was removed and cells were
incubated in dye loading buffer (HBSS with 4 μM Fluo-3,
0.04% pluronic acid, 1% FBS and 2.5 mM probenecid) for 1 h
at 37°C. Cells were washed twice with HBSS and transferred to
a FLIPR Tetra instrument (Molecular Device, Sunnyvale CA,
USA) for agonist injection and fluorescence measurements.
PAR2 agonists were added 10 s after reading commenced at
various concentrations and fluorescence was measured in real
time using excitation at 480 nm and emission at 520 nm.
HBSS was prepared in-house, while all other reagents were
purchased from Invitrogen. Plates were supplied by DKSH
(Zurich, Switzerland). Calcimycin (A23187, Invitrogen) was
used to measure maximum fluorescence, with individual
results normalized accordingly.
cAMP accumulation
LANCE Ultra cAMP assay was performed in accordance with
the manufacturer’s instructions (Perkin Elmer). In brief, cells
were dissociated from flasks by Versene (Invitrogen) on the
day of experiment. Cells (5 μL, 4 × 105 cells·per mL) were
transferred to a 384-well proxiplate (Perkin Elmer) and incu-
bated with various concentrations of GB88 (2.5 μL) for
20 min at room temperature. Forskolin (2.5 μL, 120 nM) was
then added into each well and incubated for a further 10 min
at room temperature. Finally, europium (Eu)-cAMP tracer
(5 μL) and ULight™-anti-cAMP (5 μL) were added to each
well and incubated for 1 h at room temperature. The plate
was read using a Pherastar FS fluorimeter (BMG, Germany).
ERK1/2 phosphorylation
SureFire phospho-ERK1/2 assay was performed in accordance
with the manufacturer’s instructions (Perkin Elmer). In brief,
cells were seeded overnight in 96-well tissue culture plate (∼5
× 104 cells per well). On the day of experiment, cells were
treated with various concentrations of compounds dissolved
in serum-free medium and incubated for 10 min at 37°C.
Supernatant was removed and cells were lysed with cell lysis
buffer provided by the kit. Cell lysate (4 μL) was transferred to
a 384-well proxiplate (Perkin Elmer) and incubated with reac-
tion mixture (7 μL) for 2 h at room temperature before plate
reading.
Western blot analysis
HT-29 cells were seeded at a density of 5 × 105 cells·mL−1 and
allowed to adhere overnight. Cells were then serum-starved
up to 8 h followed by treatment with 2f-LIGRLO-NH2 and
GB88 at specific concentrations. Cells were lysed in Tris buffer
(50 mM, pH 7.4) containing SDS (1%) and protease inhibitor
cocktail (Roche Applied Science). Equal amounts of proteins
were separated by SDS-PAGE and transferred onto polyvi-
nylidene fluoride membrane. Proteins were detected using
specific antibodies targeting a protein of interest: phospho-
myosin phosphatase, (MYPT1; Thr696), PKC pan, phospho-
PKC, (Thr638/641), phospho-PKC antibody sampler kit (Cell
Signaling Technology), GAPDH (Sigma-Aldrich) and PKC
epsilon (Ser729; Abcam). Relative densitometry analysis on
protein bands was performed using ImageJ software (v1.42q).
Results were normalized against control bands.
G-LISA Ras homologue gene family, member
A (RhoA) activation assay
HT-29 cells were seeded at 30% confluency and serum-starved
for 2 days prior to experiment. Cells were treated with various
agents, and cell lysates were collected by lysis buffer provided
by kit. RhoA activation was examined using G-LISA kit
(Cytoskelelon Inc., Denver, CO, USA; BK124). Briefly, cell
lysates were added 1:1 v/v to binding buffer and triplicate
assays were performed. Samples were incubated (30 min),
washed (3 times) with washing buffer, antigen-presenting
buffer was added (2 min), then incubated with anti-RhoA
antibody (45 min), washed three more times, then incubated
with secondary antibodies (45 min, room temperature). HRP
detection reagent was added and signal was read by measur-
ing absorbance at 490 nm after stopping the reaction with
2 M sulfuric acid. Total RhoA in cell lysates was measured by
RhoA ELISA kit (Cytoskeleton Inc., BK150).
Confocal microscopy of HT-29 cells
Cells were seeded on sterile glass coverslips and allowed to
adhere overnight. The cells were incubated in medium con-
taining 0.5% serum for 24 h followed by serum-starved for
another 24 h. Cells were treated with PBS, calpeptin,
2f-LIGRLO-NH2 or GB88 and fixed with 4% formaldehyde for
10 min. Cells were then permeabilized with 0.5% Triton for
5 min and incubated with fluorescein-phalloidin for 30 min
at room temperature. The slides were mounted with Prolong
Gold, and examined by an LSM-510 META inverted micro-
scope (Zeiss, North Ryde, NSW, Australia).
ELISA
Cells in 6-, 12- or 48-well plates at 80% confluence were
allowed to adhere overnight. On the day of experiment, cells
were treated with test agents for 24 h. Supernatants were then
collected and examined using BD Pharmingen ELISA set.
Briefly, the plate was coated with capturing antibody over-
night at 4°C overnight. The plate was then blocked by 10%
serum for 1 h at room temperature. Samples were added to
each well, along with standards, and allowed to incubate for
2 h at room temperature. Afterwards, HRP-conjugated anti-
body was added and incubated for a further 1 h at room
temperature. K-blue substrate (Elisa Systems, Brisbane,
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Australia) was allowed to develop for 30 min in the dark,
stopped by sulfuric acid (50 μL, 2 M), and absorbance was
measured.
Animals
All animal care and experimental procedures were approved
by the animal ethics committee of The University of Queens-
land. All studies involving animals are reported in accordance
with the ARRIVE guidelines for reporting experiments involv-
ing animals (Kilkenny et al., 2010; McGrath et al., 2010). A
total of N animals were used in the experiments described
here.
Male Wistar rats (8–9 weeks, 250 ± 20 g) were bred at the
Australia Animal Resource Centre (Canning Vale, WA, Aus-
tralia). Following Australian ethical standard animal air trans-
port, animals were housed at The University of Queensland
Biological Resources (UQBR) Animal Facility at The Australian
Institute for Bioengineering and Nanotechnology at The Uni-
versity of Queensland, Australia. Animals were housed in the
appropriate temperature/pressure environment in a 12 h
light/dark cycle, according to the standards of the accredited
holding facility, with food and water provided ad libitum. At
least 48 h habituation in the UQBR facility was provided prior
to any experimental intervention. After experimentation,
animals were humanely killed by CO2 inhalation as stipulated
by approved ethical agreements.
PAR2-induced paw oedema
Male Wistar rats (8–9 weeks) were injected with 2f-LIGRLO-
NH2 (350 μg in 100 μL isotonic saline) or trypsin (20 μg) into
the plantar surface of both hind paw pads using a 30G needle.
Inhibitors at various concentrations in saline were injected
into the plantar surface of the right hind paw pad, 30 min
before agonist, while the left hind paw pad received saline
only by injection. Paw thickness and width were measured
using digital calipers (WPI) at 0, 1, 2 and 24 h after PAR2
agonist administration. Hind paw size is expressed as %
change in area after 1 h from baseline, right (inhibitor) paw
compared with left (control) paw, and then normalized
against maximum swelling induced by agonist alone.
Data analysis
Data were analysed in GraphPad Prism (GraphPad Software,
San Diego, CA, USA) using ANOVA or Student’s t-test, with
values expressed as mean ± SEM (n ≥ 3). Data are presented as
the mean value of the entire data set. Significance was deter-
mined as P < 0.05. Concentration-response curves were fitted
in GraphPad Prism with a standard Hill slope of 1 (three-
parameter fit).
Materials
PAR2 activating peptide agonist (2f-LIGRLO-NH2), non-
peptide agonist (GB110) and non-peptide antagonist (GB88)
were synthesized in-house as described (Barry et al., 2010;
Suen et al., 2012). ELISA sets were purchased from BD Pharm-
ingen (San Jose, CA, USA). SureFire phosphor-ERK1/2 kit and
LANCE Ultra cAMP kit were purchased from Perkin Elmer.
G-LISA kit was purchased from Cytoskeleton Inc. Pertussis
toxin (PTX) was purchased from Abacus ALS (Brisbane, Aus-
tralia). Y-27632, Gö6983 and FITC-labelled phalloidin were
purchased from Sigma-Aldrich. U0126 was purchased from
Merck. Prolong Gold was purchased from Invitrogen.
Results
GB88 is a PAR2 antagonist of Ca2+ release
and PKC phosphorylation
Recently, we discovered an orally active PAR2 antagonist
(GB88) that inhibited PAR2-, but not PAR1-, induced intrac-
ellular calcium mobilization in multiple human cell types
treated with peptide, non-peptide or protease agonists of
PAR2 (Barry et al., 2010; Suen et al., 2012). Here, we use a
fluorescence-based binding assay (Hoffman et al., 2012) to
show that GB88 directly competes with a Eu-tagged peptide
agonist of PAR2, namely 2f-LIGRLO-NH2 (Figure 1A and 1B).
CHO cells transfected with human PAR2 were used because a
high level of PAR2 expression is required to allow binding
measurements. On human non-transfected colorectal HT-29
cells, GB88 behaved as a full antagonist in inhibiting Ca2+
release induced by the PAR2 agonist 2f-LIGRLO-NH2
(Figure 1C and 1D). GB88 was also a PAR2 antagonist in
inhibiting Ca2+ release in CHO-hPAR2 cells (Supporting Infor-
mation Fig. S1), but did not bind to untransfected CHO cells
or induce Ca2+ release in HT-29 cells at concentrations where
it was an antagonist. In terms of Ca2+ release, GB88 behaved
as a PAR2-specific antagonist with no agonist activity up to
10 μM concentration (Supporting Information Figs S2 and
S3) in HT-29 cells. GB88 inhibition of 2f-LIGRLO-NH2-
induced calcium release was not Gs-dependent, as cholera
toxin (CTX) did not decrease the response induced by the
agonist (Supporting Information Fig. S4). PAR2 activation
activated various subtypes of PKC (Reibman et al., 2000;
Amadesi et al., 2009; Chen et al., 2011; Huang et al., 2012).
When HT-29 cells were treated here with 2f-LIGRLO-NH2,
there was an increase in phosphorylated PKCα/β (Figure 1E
and Supporting Information Fig. S5) that was prevented by
GB88 treatment (Figure 1F). These results indicate that GB88
is a full antagonist in inhibiting the PAR2-Gq/11-Ca2+-PKC sig-
nalling axis in vitro in cells expressing human PAR2.
GB88 inhibits PAR2-mediated
cytokine release
PAR2 activation has previously been associated with inflam-
matory cytokine production, so we investigated whether
GB88 was able to antagonize cytokine release. In HT-29 cells,
GB88 blocked the secretion of IL-8 induced by a PAR2 agonist
(Supporting Information Fig. S6). Effects of PAR2 agonist and
antagonist were also examined in primary HTEC of the
kidney, as these cells have been previously reported to
respond strongly to PAR2 activation by releasing some
cytokines (Vesey et al., 2007),. Indeed, GB88 (10 μM) did sig-
nificantly reduce production of IL-8, IL-6, TNF-α and GMCSF
induced by 2f-LIGRLO-NH2 (1 μM) as measured by ELISA
(Figure 2). For comparison, cytokine production was abol-
ished by blocking the activity of PKC using the commercially
available PKC inhibitor, Gö6983. GB88 alone (10 μM) did not
cause any significant increase in cytokine secretion.
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GB88 attenuates forskolin-induced cAMP
accumulation via PAR2-Gi/o
GB88 was examined for effects in other PAR2-mediated intra-
cellular pathways. It induced a similar response to the PAR2
agonist 2f-LIGRLO-NH2 in down-regulating forskolin-
induced cAMP levels in CHO-hPAR2 cells (Figure 3A and 3B)
and in HT-29 cells (Figure 3C and 3D). Neither GB88 nor
2f-LIGRLO-NH2 had any effect on cAMP in untransfected
CHO cells (Figure 3A and 3B). In HT-29 cells, this PAR2-
mediated response induced by either 2f-LIGRLO-NH2 or GB88
was abolished by pretreatment of the same cells with PTX
(200 ng·mL−1, 24 h), indicating that the response was Gi/o
dependent (Figure 3C and 3D). The results reveal that GB88
behaves like other PAR2 agonists in reducing forskolin-
induced cAMP accumulation via activating the PAR2-Gi/o sig-
nalling pathway.
GB88 stimulates RhoA activity
With respect to the G12/13 pathway, HT-29 cells were treated
with either 2f-LIGRLO-NH2 or GB88 and examined for for-
mation of the characteristic actin stress fibres that result from
RhoA activation. Calpeptin (CN01), a known RhoA activator,
was used as positive control. Under confocal microscopy, cells
treated with 2f-LIGRLO-NH2 or GB88 both showed rearrange-
ment of actin filaments to the same extent as the positive
control (Figure 4A). This induction of RhoA activity by both
treatments was confirmed using G-LISA to directly measure
production of RhoA protein. Both PAR2 ligands were able to
stimulate RhoA release (Figure 4B). Downstream phosphor-
ylation of MYPT, known to be a messenger associated with
RhoA and Rho-associated kinase (ROCK), was also observed.
Both PAR2 ligands increased MYPT phosphorylation
(Figure 4C and 4D). Thus, GB88 behaved like other PAR2
Figure 1
GB88 is an antagonist of the PAR2-Ca2+-PKC signalling axis. (A) 2f-LIGRLO-NH2 competed in a concentration-dependent manner with 300 nM
Eu-tagged 2f-LIGRLO-NH2 (KD 240 nM, n = 6) in a receptor binding assay in CHO-hPAR2. (B) GB88 competed in a concentration-dependent
manner with 300 nM Eu-tagged 2f-LIGRLO-NH2 (Ki 7.7 μM, n = 3) in CHO-hPAR2 cells. (C) 2f-LIGRLO-NH2-induced intracellular calcium release
(EC50 340 nM, n = 12) in a concentration-dependent manner in HT-29 cells. (D) GB88 inhibited 2f-LIGRLO-NH2 (1 μM) induced intracellular
calcium release (IC50 560 nM, n = 3) in HT-29 cells. (E) Time-course of PKC phosphorylation by 2f-LIGRLO-NH2 and GB88 (n = 6) in HT-29 cells.
(F) GB88 blocked PKC phosphorylation induced by PAR2 in HT-29 cells (n = 6). (E, F) One representative Western blot is shown, bar chart results
are for six independent experiments (n = 6). Data shown are means ± SEM. n, number of independent experiments, **P < 0.01, ***P < 0.001;
significant differences as indicated.
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agonists in up-regulating G12/13 signalling with RhoA
activation.
GB88 phosphorylates ERK1/2 via PAR2
Both 2f-LIGRLO-NH2 and GB88 induced ERK1/2 phosphor-
ylation in CHO-hPAR2 cells and in HT-29 cells, whereas no
effect was detected in untransfected CHO cells (Figure 5A and
5B). This is consistent with GB88 being a PAR2-selective
agonist via this pathway. However, unlike the other agonist-
like effects of GB88 above, the GB88-induced response was
only ∼50% of the magnitude of the response to 2f-LIGRLO-
NH2. In order to delineate the signalling pathways associated
with ERK1/2 phosphorylation, HT-29 cells were treated with
inhibitors of various intracellular messengers (Figure 5C–F).
The mitogen-activated kinase (MEK)1/2 inhibitor, U0126,
completely abolished the effects of both PAR2 ligands, while
treatment with RhoA inhibitor (Y-27632) resulted in slight
changes in compound potencies. PTX was inactive in regu-
lating levels of pERK1/2, consistent with the Gi/o coupling not
being involved in this event. The PKC inhibitor, Gö 6983,
failed to cause any effect on ERK1/2 phosphorylation induced
by GB88. However, it did significantly reduce the 2f-LIGRLO-
NH2-induced response by ∼50%, bringing it down to a level
similar to GB88. Of the four commercial inhibitors tested,
only the PKC inhibitor showed differential effects on the two
PAR2 ligands examined.
GB88 inhibits PAR2-induced paw oedema
To correlate with the above in vitro findings, the properties of
GB88 were compared with those of the commercially avail-
able signalling pathway inhibitors above in a PAR2-induced
paw oedema in Wistar rats, an acute inflammation model in
vivo. The PAR2 agonists, 2f-LIGRLO-NH2 (350 μg) or trypsin
(20 μg), were given by intra-plantar (i.pl.) injection to rat
paws to induce an acute paw oedema in vivo. Oral adminis-
tration of GB88 (10 mg·kg−1) 3 h prior to induction of paw
oedema, commensurate with its Tmax of 4 h (Lohman et al.,
2012a; Suen et al., 2012), reduced (>50%) the swelling medi-
ated by PAR2 activation after 30 min to 2 h (Figure 6A and
6B). Elsewhere, we have reported that GB88 does not inhibit
rat paw oedema induced by PAR1 agonists thrombin and the
pentapeptide TFLLR-NH2 (Suen et al., 2012). As GB88 was an
antagonist of PAR2-induced paw oedema, but behaved simi-
larly to PAR2 agonists in the in vitro assays except for those
associated with intracellular calcium and PKC phosphoryla-
tion, we also examined the effect of the PKC inhibitor
(Gö6983, 1 μM and 10 μM) in the same in vivo rat model of
acute inflammation. This inhibitor was locally injected into
the hind paw pads 30 min prior to i.pl. injection of either
2f-LIGRLO-NH2 or trypsin, resulting in significant reduction
in PAR2-induced paw oedema (up to 90%; Figure 6C and 6D).
Similar experiments were performed with inhibitors of other
secondary messengers of PAR2 signalling pathways, including
U73122 (PLCβ), U0126 (MEK1) and PTX (Gi/o), and all except
the PLCβ inhibitor failed to reduce PAR2-mediated paw
oedema (Supporting Information Fig. S7). Thus, orally deliv-
ered systemic GB88 had a similar anti-inflammatory effect in
rat paws as a PKC inhibitor (and possibly any PAR2-Gq/11
pathway inhibitor) locally administered to rat paws in this
model of paw oedema. This directly contrasts with the pro-
inflammatory effects of the PAR2 agonists 2f-LIGRLO-NH2
and trypsin (Figure 6), as well as tryptase, which all induce rat
paw oedema in this inflammatory model (Lohman et al.,
2012b; Suen et al., 2012).
Thus, GB88 has dual functions mediated through PAR2. It
was a selective antagonist of the PAR2-Gq/11-Ca2+-PKC signal-
ling pathway (Figure 1), exerting anti-inflammatory activity
like Gö6983 both in vivo and in vitro, as shown by inhibiting
PAR2-induced paw oedema in rats and by inhibiting secretion
of inflammatory cytokines from human cells (IL8, IL6, TNF-α,
GMCSF) stimulated with the PAR2 agonist 2f-LIGRLO-NH2
(Figure 2). However, GB88 was a PAR2 agonist in other path-
ways in vitro, behaving like 2f-LIGRLO-NH2 in activating Gi/o
(Figure 3), G12/13 (Figure 4) and ERK1/2 (Figure 5) signalling
pathways. By contrast, PAR2 agonists like trypsin, SLIGRL-
NH2, 2f-LIGRLO-NH2 all show pro-inflammatory effects in
vitro and in vivo in the assays described, unlike the anti-
inflammatory effects of GB88.
Discussion and conclusions
Protein and peptide-activated GPCRs are embedded in the
plasma membrane of cells and are pivotal mediators in
disease (Tyndall et al., 2005; Blakeney et al., 2007). About
30% of all pharmaceutical agents activate (agonist) or inhibit
(antagonist) GPCRs. Many GPCR ligands were discovered by
screening chemical libraries for GPCR binding, followed by
optimizing for higher affinity, selectivity and functional
potency in one or two in vitro assays (Klabunde and Hessler,
2002; Blakeney et al., 2007). Compounds assigned as agonists
Figure 2
GB88 blocks PAR2 induced cytokine release in HTEC kidney cells.
GB88 (10 μM, 30 min) inhibited >50% of IL-8 (A), IL-6 (B), TNF-α (C)
and GM-CSF (D) secretion induced by PAR2 activation (2f-LIGRLO-
NH2 1 μM, 24 h). Inhibition of PKC by Gö6983 (1 μM, 30 min) also
showed decreased secretion of these cytokines. Treatment with GB88
or Gö6983 failed to change cytokine release. Data shown are means
± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P
< 0.001; significant differences as indicated.
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or antagonists have historically been assumed to be so across
all functions mediated by that receptor. However, this is now
known not to be always true, due to ligand-induced biased
signalling (Shukla et al., 2008; Rajagopal et al., 2010; Kenakin,
2011; 2012). Two structurally similar agonists, even for the
same GPCR subtype, can activate different intracellular sig-
nalling cascades due to subtle differences in interactions with
the GPCR (Quirk et al., 2007; Shukla et al., 2008; Rajagopal
et al., 2010; Kenakin, 2012), resulting in different ligand-
bound receptor conformations. In turn, intracellular G
protein coupling to a GPCR can also influence extracellular
ligand binding (Kobilka and Deupi, 2007; Kobilka and
Schertler, 2008; Kobilka, 2011). A biased ligand differentially
affects certain signal transduction pathways, and can poten-
tially exert more refined control over GPCR-mediated cell
signalling by activating or inhibiting a particular signalling
pathway. To date, most GPCR research on biased signalling
has focused on distinguishing G-protein-dependent from
independent (e.g. ß-arrestin) signalling. A role for ß-arrestin
was recently identified in PAR2-induced responses in lung
tissues, with an opposing physiological effect between
ß-arrestin and G-protein heterotrimers (Nichols et al., 2012).
However, in principle, biased signalling can refer to differ-
ences between any signalling pathways and may profoundly
influence whether ‘agonist’ or ‘antagonist’ properties meas-
ured in vitro translate into different in vivo properties.
In this study, different G-protein-coupled PAR2-
dependent pathways were assessed for effects of an orally
active ligand known as GB88. Previously, we reported that
GB88 was an antagonist of PAR2-activating peptide agonists
(2f-LIGLRO-NH2, SLIGKV-NH2, SLIGRL-NH2), non-peptide
agonists (GB110), and protease agonists (trypsin, tryptase), as
measured by intracellular calcium mobilization in different
human cell types (Lohman et al., 2012a; Suen et al., 2012). In
that assay, GB88 had no agonist activity and was selective for
PAR2 over PAR1 agonists thrombin or pentapeptide TFLLR, or
the PAR4 agonist hexapeptide AYPGKF, in human cells and in
a PAR2-induced rat paw oedema model. In the present study,
GB88 was found to compete with 2f-LIGRLO-NH2 in a com-
petitive ligand-binding assay by measuring hPAR2 affinity on
CHO-hPAR2 and to antagonize 2f-LIGRLO-NH2-induced Ca2+
release; yet it behaved like PAR2 agonists in attenuating
forskolin-induced cAMP accumulation and inducing ERK1/2
phosphorylation. In HT-29 cells, GB88 is an antagonist of
PAR2 by blocking Ca2+ release, PKC phosphorylation and IL-8
secretion, but it is an agonist in activating Gi/o, increasing
pERK1/2, and increasing RhoA activity and MYPT phospho-
rylation. In primary human kidney cells, GB88 reduced secre-
tion of several inflammatory cytokines induced by PAR2
agonist 2f-LIGRLO-NH2, and in rats it blocked PAR2-mediated
paw oedema. These differential effects of GB88 indicate
pathway-selective modulation of PAR2, with agonist or
Figure 3
GB88 down-regulates cAMP via PAR2-Gi/o. (A) 2f-LIGRLO-NH2 dose dependently down-regulated forskolin-stimulated cAMP in CHO cells
transfected with human PAR2 (EC50 70 nM, n = 3), but was inactive in untransfected CHO cells (dotted line). (B) GB88 dose-dependently
down-regulated cAMP in CHO-hPAR2 cells as did the PAR2 agonist 2f-LIGRLO-NH2 (EC50 120 nM, n = 3), but was inactive in untransfected CHO
cells. Thus, the response was PAR2 dependent. (C–D) Dose-dependent down-regulation of forskolin-stimulated cAMP by 2f-LIGRLO-NH2 (C; EC50
4 nM) and GB88 (D; EC50 600 nM) in HT-29 cells (n = 12), both inhibited with PTX (200 ng·mL−1, 24 h, n = 3). This indicates that down-regulation
of cAMP was via Gi/o activation. Data shown are means ± SEM, n, number of independent experiments.
1bs_bs_query
2bs_bs_query
3bs_bs_query
4bs_bs_query
5bs_bs_query
6bs_bs_query
7bs_bs_query
8bs_bs_query
9bs_bs_query
10bs_bs_query
11bs_bs_query
12bs_bs_query
13bs_bs_query
14bs_bs_query
15bs_bs_query
16bs_bs_query
17bs_bs_query
18bs_bs_query
19bs_bs_query
20bs_bs_query
21bs_bs_query
22bs_bs_query
23bs_bs_query
24bs_bs_query
25bs_bs_query
26bs_bs_query
27bs_bs_query
28bs_bs_query
29bs_bs_query
30bs_bs_query
31bs_bs_query
32bs_bs_query
33bs_bs_query
34bs_bs_query
35bs_bs_query
36bs_bs_query
37bs_bs_query
38bs_bs_query
39bs_bs_query
40bs_bs_query
41bs_bs_query
42bs_bs_query
43bs_bs_query
44bs_bs_query
45bs_bs_query
46bs_bs_query
47bs_bs_query
48bs_bs_query
49bs_bs_query
50bs_bs_query
51bs_bs_query
52bs_bs_query
53bs_bs_query
54bs_bs_query
55bs_bs_query
56bs_bs_query
57bs_bs_query
58bs_bs_query
59bs_bs_query
60bs_bs_query
BJPPathway-selective PAR2 antagonism
British Journal of Pharmacology (2014) •• ••–•• 7
JOBNAME: No Job Name PAGE: 8 SESS: 9 OUTPUT: Thu Jun 5 17:18:37 2014 SUM: 6798DCCC
/Xpp84/wiley_journal_B-C/BPH/bph_v0_i0/bph_12757
antagonist activity dependent on the signal transduction
being examined but not on the cell type, at least for these
cells examined here. Elsewhere, GB88 alone reportedly
recruited PAR2-dependent ß-arrestin-1/2 to the plasma mem-
brane but did not either induce or inhibit receptor internali-
zation (Adams et al., 2011; Hollenberg et al., 2014).
GB88 behaved like 2f-LIGRLO-NH2 in inducing ERK1/2
phosphorylation. Increased pERK1/2 was observed for cells
treated with either 2f-LIGRLO-NH2 or GB88. However, unlike
the comparable levels of cAMP reduction or RhoA activation
by both compounds, GB88 only induced 50% of the increase
in pERK1/2 that was caused by 2f-LIGRLO-NH2. Only
2f-LIGRLO-NH2-induced pERK1/2 was sensitive to PKC inhi-
bition, and there was no significant difference in pERK1/2
between GB88 and 2f-LIGRLO-NH2 in cells pretreated with
PKC inhibitor. As inhibitors of various G-protein-coupled
pathways were ineffective against GB88-induced ERK1/2
phosphorylation, it is likely that this proceeds via a
G-protein-independent pathway, possibly via β-arrestin1/2.
In summary, if we had not assessed antagonism of Ca2+
and PKC signalling by GB88, this compound would have
been considered a weak agonist in the other pathways exam-
ined herein and its biased signalling properties and anti-
inflammatory properties would have been missed. Could the
antagonist properties in various animal models be explained
by GB88 being a pathway-selective PAR2 agonist that simply
fails to recruit Gq/11? If so, why does it inhibit other agonists
only in this pathway. Is it possible that GB88 antagonizes
PAR2-mediated Ca2+ release, cytokine production and paw
oedema by biasing the receptor toward G12/13, Gi/o or even
β-arrestin1/2 activation, thereby preventing a typical agonist
(such as 2f-LIGRLO-NH2) from activating the Gq/11 pathway?
If so, why don’t other agonists that activate these pathways
behave similarly. Finally, we have shown elsewhere that GB88
is a competitive antagonist of 2f-LIGRLO-NH2 (Suen et al.,
2012), so why should it be viewed as an agonist. While the
precise mechanism of antagonism remains uncertain, it is
clear that GB88 has beneficial inhibitory properties of PAR2
activation in a key inflammatory pathway. This is evidenced
here by GB88 inhibiting (i) PAR2-Gq-Ca2+-PKC-cytokine sig-
nalling in human cells, (ii) PAR2-induced inflammatory rat
paw oedema, and (iii) in our recent in vivo studies, PAR2- and
TNBS-induced experimental colitis in rats (Lohman et al.,
2012b), collagen-induced arthritis in rats (Lohman et al.,
Figure 4
GB88 activates RhoA via PAR2. (A) Confocal microscopy images of HT-29 cells treated with various agents [control; Calpeptin (CN01),
0.1 mg·mL−1, 20 min; 2f-LIGRLO-NH2, 10 μM, 20 min; GB88, 50 μM, 20 min]. Actin filament was stained with FITC-phalloidin (200 nM, 30 min).
(B) RhoA activation in HT-29 cells was measured by G-LISA. Serum-free medium was used as negative control and calpeptin (CN01, 0.1 mg·mL−1,
20 min) was used as positive control. Both 2f-LIGRLO-NH2 (10 μM, 20 min) and GB88 (50 μM, 20 min) up-regulated RhoA activition (n = 3).
(C–D) Phosphorylation of MYPT by (C) 2f-LIGRLO-NH2 (10 μM) and (D) GB88 (50 μM) in HT29 cells, indicating an increase in activity of ROCK.
One representative Western blot is shown, bar chart results are for three independent experiments (n = 3). Optical densities were normalized
against controls of individual blots. Data shown are means ± SEM. n, number of independent experiments; n.s. not statistically significant, *P <
0.05, **P < 0.01, ***P < 0.001; significant differences as indicated.
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2012a), and diet-induced metabolic dysfunction, adiposity,
cardiac fibrosis and remodelling in rats (Lim et al., 2013).
Thus, at least in the context of the various cells and the
disease model examined here and those in our recent publi-
cations, GB88 can be considered as a valuable pathway-
selective antagonist of PAR2, an antagonist with a biased
signalling profile.
As GB88 is an antagonist of PAR2-mediated intracellular
calcium release and PKC phosphorylation, we investigated
whether a PKC inhibitor could also mimic properties of
GB88. PAR2-mediated PKC activation has been reported to be
essential in GM-CSF production in PAR2-activated airway
epithelial cells, and PAR2-PKC activation has been associated
with neurogenic inflammation and neuropathic pain, possi-
bly through increased PKA activity and sensitization of
TRPV1, TRPV4 and TRPA1 channels (Reibman et al., 2000;
Amadesi et al., 2009; Chen et al., 2011; Huang et al., 2012;
channels nomenclature follows LAexadner et al., 2013b). In
this study, PAR2-mediated secretion of proinflammatory
cytokines and PAR2-induced rat paw oedema were both
inhibited by the PKC inhibitor Gö6983, as well as by GB88.
This supported our findings that GB88 inhibits the PAR2-Gq-
Ca2+-PKC axis, whereas its agonist properties have no role in
its anti-inflammatory effects in the rat paw oedema model.
PAR2 activation is known to activate many different
genes, physiological processes and metabolic pathways (Barry
Figure 5
GB88 phosphorylates ERK1/2 via PAR2. (A–B), Concentration-dependent phosphorylation of ERK1/2 by 2f-LIGRLO-NH2 (A; EC50 250 nM) or GB88
(B; EC50 1.3 μM) in CHO-hPAR2 cells (solid lines), compared with no activity in untransfected CHO cells (dotted lines). This suggests a
PAR2-dependent effect. (C) ERK1/2 phosphorylation of both PAR2 ligands in HT29 cells was abolished by the MEK1/2 inhibitor, U0126 (10 μM,
30 min). (D) Gi/o inhibitor, PTX (200 ng·mL−1, 24 h) failed to have any significant effects on ERK1/2 phosphorylation induced in HT29 cells by both
PAR2 ligands. (E) 2f-LIGRLO-NH2-induced ERK1/2 phosphorylation in HT29 cells was significantly reduced by PKC inhibitor, Gö6983 (1 μM,
30 min). The reduced level was similar for GB88. Gö6983 was inactive against GB88-induced response. (F) ERK1/2 phosphorylation in HT29 cells
in the presence of ROCK inhibitor, Y-27632 (1 μM, 2 h). Data shown are means ± SEM of three independent experiments.
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et al., 2006; Suen et al., 2010; Yau et al., 2013), so the prospect
of using rationally designed PAR2-binding ligands to inhibit
only one PAR2-mediated signalling pathways associated with
a particular diseased state is an exciting opportunity that may
also be possible for other GPCRs. There have been seemingly
paradoxical reports of PAR2 being both pro- and anti-
inflammatory (see Barry et al., 2006; Yau et al., 2013), depend-
ing upon the context of cell or animal experiments
conducted or disease models studied. The new findings here
provide a possible explanation for such opposing actions,
suggesting that it may be possible for some ligands to activate
certain PAR2-mediated pathways while blocking others,
enabling PAR2-mediated disease intervention without affect-
ing beneficial or protective PAR2-mediated physiological
responses. Importantly, this potentially useful ligand-induced
fine-tuning control over PAR2-mediated cellular responses
cannot be predicted or interrogated by receptor knockouts,
knockdowns or phenotypic screens and this highlights the
value of a biased ligand like GB88 in offering unique mecha-
nistic insights to relationships between extracellular ligand
binding, intracellular signalling, physiological responses and
disease modulation.
The general prospect of ligand-induced biased signalling
via GPCRs opens a new dimension for drug design, with the
novel possibility of exerting a new level of fine-tuning control
and specificity over intracellular regulation that could be of
considerable pharmacological significance and therapeutic
potential. Extracellular ligands that differentially regulate
downstream intracellular signalling through protein recep-
tors located in the plasma membrane, activating or inhibiting
selective signalling pathways associated with specific diseases,
may present new opportunities for drug design. In this study,
we have identified biased signalling by the PAR2 ligand GB88
in human cells. In HT-29 cells, we discovered that GB88 was
a biased antagonist of PAR2-Gq/11-dependent Ca2+ release and
Figure 6
GB88 blocks PAR2-induced paw oedema in rats. (A–B) GB88 (10 mg·kg−1 p.o., 3 h prior) inhibited rat paw oedema induced by i.pl. injection of
PAR2 agonist, 2f-LIGRLO-NH2 (A, 350 μg) or trypsin (B, 20 μg). (C–D) PKC inhibitor, Gö6983 (1 and 10 μM, intraplanar), inhibited Wistar rat paw
oedema induced by i.pl. injection of PAR2 agonist 2f-LIGRLO-NH2 (C, 350 μg) or trypsin (D, 20 μg). Samples were compared with 2f-LIGRLO-NH2
or trypsin-treated controls. Data shown are means ± SEM; n.s. not statistically significant, *P < 0.05, **P < 0.01, ***P < 0.001; significant differences
as indicated.
Figure 7
Schematic diagram of effects of GB88 on PAR2-mediated signalling.
GB88 activates (arrows) three of four PAR2-coupled pathways shown,
and selectively inhibits (T arrow) the PAR2-Gq/11-Ca2+-PKC pathway.
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PKC activation, as well as blocking secretion of several
cytokines in human kidney cells. On the other hand, GB88
behaved as a PAR2 agonist in activating PAR2-mediated Gi/o-
dependent cAMP down-regulation, PAR2-mediated G12/13-
dependent RhoA activation, and PAR2-mediated ERK
phosphorylation. These novel findings reveal new opportu-
nities to selectively modulate the PAR2-Gq/11 pathway for
therapeutic benefit in inflammatory diseases. There are few
known specific inhibitors of the Gq/11 signalling pathway
(Nishimura et al., 2010) and the properties of GB88 in human
cells and rat inflammation contribute to our mechanistic
understanding of PAR2 signalling and of Gq/11-Ca2+-PKC sig-
nalling in inflammation. An exciting implication is the pos-
sibility of harnessing pathway-selective antagonism without
preventing activation of other, potentially protective or ben-
eficial, physiological effects mediated by other PAR2-coupled
signalling pathways. We expect that this work will stimulate
further searches for, and mechanistic studies of, biased
ligands of PAR2 and other GPCRs, for which ligand-induced
biased signalling is not fully explored.
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Figure S1 GB88 blocked 2f-LIGRLO-NH2-induced intracel-
lular calcium release in CHO-hPAR2. Cells were incubated
with various concentrations of GB88 for 15 min, then treated
with 2f-LIGRLO-NH2 (1 μM) and monitored for intracellular
calcium release.
Figure S2GB88 induced intracellular calcium release at high
concentration in HT-29 cells.
Figure S3 Intracellular calcium release by PAR2 ligands in
HT-29 cells. Calcimycin was used a control. Cells were treated
with 2f-LIGRLO-NH2 (1 μM) and GB88 (10 μM) and fluores-
cence measured for 30 min after compound addition.
2f-LIGRLO-NH2 showed similar maxima as calcimycin and
GB88 showed no significant difference from buffer alone.
Figure S4 2f-LIGLRO-NH2 increased intracellular calcium
release independent of Gs in HT-29 cells. HT-29 cells were
treated with cholera toxin (200 ng·mL−1, 24 h) and treated
with 2f-LIGRLO-NH2 or forskolin for calcium release. Forsko-
lin failed to induce intracellular calcium release and CTX has
no effect on PAR2-mediated Ca2+ response.
Figure S5 2f-LIGRLO-NH2 and GB88 failed to increase phos-
phorylation of PKC subtypes in HT-29 cells. Cells were treated
with 2f-LIGRLO-NH2 (1 μM) or GB88 (10 μM) for various
durations and examined by Western blot using phosphor-
specific antibodies.
Figure S6 GB88 blocks IL-8 secretion in HT-29 cells. Cells
were treated with 2f-LIGRLO-NH2 (1 μM, 24 h) with various
concentration of GB88. Supernatants or cell lysates were
collected and analysed by ELISA. GB88 was able to block
2f-LIGRLO-NH2-induced IL-8 secretion and no significant
changes in level of IL-8 in cells.
Figure S7 Effects of inhibitors on PAR2-induced paw
oedema in rat. PLCβ (100 μM, 30 min) inhibited Wistar rat
paw oedema induced by intraplantar injection of PAR2 ago-
nists, 2f-LIGRLO-NH2 (A, 350 μg) or trypsin (B, 20 μg). Other
inhibitors [MEK1/2 (U0126, 10 μM) or Gi/o (PTX, 5 μg)] failed
to cause any significant changes. n = 3, ***P < 0.001.
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